ClinicalTrials.gg
CompletedNCT01714947Updated Oct 31, 2018Results posted

Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib

A Phase 1 interventional study of [^14C]-alisertib and alisertib in Advanced Solid Tumors and Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-31.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Lymphoma by Takeda — 1 open to participants now, 2 under way, none of them phase 3. Lymphoma · Takeda.

Enrollment
23rd of 23
3 · median 36
Started
2013
with 4 others
Phase 1
12 of 26
none open now
Registered
9th of 26
by date

Among the 26 studies in Lymphoma by Takeda, this one is the 23rd largest by enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2013, is one of 12 in phase 1, and was the 9th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

1 of the 26 studies in Lymphoma by Takeda is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Lymphoma by Takeda, or all of them as a file.
02

Study summary

The purpose of this study is to assess the mass balance (i.e. cumulative excretion of total radioactivity [TRA] in urine and feces) of alisertib and pharmacokinetic (PK) of alisertib in plasma and urine, and of TRA in plasma and whole blood.

Read the detailed description

The drug being tested in this study is called alisertib (MLN8237). Alisertib is being tested to treat participants who have advanced solid tumors or lymphomas. This study looked at mass balance, pharmacokinetics (PK), metabolism, elimination and safety of alisertib.

The study enrolled 3 patients. The study consisted of 2 parts: Part A and Part B. Participants received:

  • [\^14C]-alisertib 35 mg in Part A
  • alisertib 50 mg in Part B

Participants were asked to take a single dose of [\^14C]-alisertib oral solution containing 80-100 μCi of total radioactivity (1.19-1.48 mCi/mmol) in Part A and alisertib 50 mg, orally, twice daily for 7 days in 21-day cycles until disease progression or unacceptable toxicity in Part B.

This single center trial was conducted in United States. The overall time to participate in this study was up to 117 days. Participants remained confined to clinic in Part A and made multiple visits to the clinic in Part B. Participants were contacted 30 days after last dose of alisertib in Part A (if not continuing in Part B), or were contacted by telephone or a final visit 30 days after receiving their last dose of alisertib in Part B for a follow-up assessment.

03

Conditions studied

  • Advanced Solid Tumors
  • Lymphoma

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each participants must meet all of the following inclusion criteria to be enrolled in the study:

  • 18 years or older.
  • or cytologically confirmed and/or advanced solid tumors or lymphomas for which standard curative or life-prolonging treatment does not exist, or is no longer effective or tolerable.
  • (ECOG) performance status 0 or 1.
  • Expected survival longer than 3 months from enrollment in the study.
  • Radiographically or clinically evaluable tumor.
  • Suitable venous access for the conduct of blood sampling.
  • Recovered from the reversible effects of prior antineoplastic treatment (with the exception of alopecia and Grade 1 neuropathy).
  • Female participants who are for at least 1 year OR are surgically sterile OR if of , agree to practice 2 effective methods of at the same time.
  • Male participants who agree to practice effective barrier contraception during the entire study and through 4 months after the last dose of study drug OR agree to abstain from heterosexual intercourse.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following exclusion criteria are not to be enrolled in the study:

  • Female participants who are lactating or have a positive serum pregnancy test.
  • Treatment with any products or systemic antineoplastic treatment within 21 days before the first dose of alisertib.
  • Medical conditions requiring daily, chronic, or regular use of proton pump inhibitors(PPIs) within 7 days preceding the first dose of alisertib, or H2-receptor antagonists within 24 hours preceding the first dose of alisertib.
  • Participants requiring systemic anticoagulation (excluding low-dose aspirin, or low-dose anticoagulation to maintain patency of venous access devices). Low molecular weight heparin, administered as preventive treatment, is allowed if the participant has tolerated treatment with a stable dose and schedule without bleeding complications for more than 1 month.
  • Major surgery within the 14 days preceding the first dose of alisertib.
  • Infection requiring systemic intravenous (IV) antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection.
  • Life-threatening or uncontrolled medical illness unrelated to cancer.
  • Ongoing nausea or vomiting that is Grade 2 or worse in intensity.
  • Diarrhea that is Grade 2 or worse in intensity or use of an antimotility agent to control diarrhea to an intensity of Grade 1 or lower level.
  • Known GI disease or GI procedures that could interfere with the oral absorption, excretion, or tolerance of alisertib.
  • History of urinary and/or fecal incontinence.
  • History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness such as severe .
  • Inability to swallow tablets, or inability or unwillingness to avoid taking anything by mouth except for water and prescribed medications for 2 hours before and 1 hour after the first dose of alisertib.
  • Inadequate bone marrow or other organ function as specified in study protocol.
  • Any cardiovascular condition specified in the study protocol.
  • Known or suspected (HIV) positive or surface antigen-positive status, or known or suspected active infection.
  • Inability to comply with study visits and procedures including required inpatient confinement (approximately 11-17 days).

Please note that there are additional exclusion criteria. The study center will determine if you meet all of the criteria.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Alisertib

    Part A: \[\^14C\]-alisertib 35 mg, oral solution containing 80 - 100 microcuries (μCi) of total radioactivity (1.19 - 1.48 mCi/mmol), orally, single dose on Day 1. Part B: Alisertib 50 mg, enteric coated tablets, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 3 Cycles).

    Drug: [^14C]-alisertib · Drug: alisertib

Interventions

  • \[\^14C\]-alisertib oral solution

    Also known as: MLN8237

  • Alisertib enteric coated tablets

    Also known as: MLN8237

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  2. Tmax: Time of First Occurrence of Cmax for Alisertib and Drug-Related Material in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  3. AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  4. AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  5. T1/2: Terminal Half Life for Alisertib and Drug-Related Material in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  6. CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Plasma Concentration for Alisertib Following a Single Dose of [^14C]-Alisertib Oral Solution

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  7. Ratio of Whole Blood Total Radioactivity (TRA) Cmax to Plasma TRA Cmax

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  8. Ratio of Alisertib Plasma Cmax to Drug-Related Material TRA Plasma Cmax

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  9. Ratio of Whole Blood TRA AUClast to Plasma TRA AUClast

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  10. Ratio of Alisertib Plasma AUClast to Drug-Related Material TRA Plasma AUClast

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  11. Ratio of Whole Blood TRA AUC∞ to Plasma TRA AUC∞

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  12. Ratio of Alisertib Plasma AUC∞ to Drug-Related Material TRA Plasma AUC∞

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  13. Fe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Urine

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  14. Fe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Feces

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  15. Ae: Amount of [^14C]-Alisertib Excreted in Urine

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  16. Ae: Amount of [^14C]-Alisertib Excreted in Feces

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  17. Percent of Total Radioactivity (TRA) in Urine and Feces

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  18. Fe: Fraction of Administered Dose of Alisertib Excreted in Urine

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  19. Ae: Amount of Alisertib Excretion in Urine

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

  20. Renal Clearance (CLR) of Alisertib

    Time frame: Predose and multiple timepoints post-dose (up to 240 hours)

Secondary outcomes

  1. Percentage of Alisertib Metabolites in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution

    Total radioactive peak distributions of metabolites in 0 to 192 hours pooled plasma samples from participants.

    Time frame: Predose and multiple timepoints post-dose (0 to 192 hours)

  2. Percentage of Alisertib Metabolites in Urine Following a Single Dose of [^14C]-Alisertib Oral Solution

    Total radioactive peak distributions of metabolites in 0 to 192 hours pooled urine samples from participants.

    Time frame: Predose and multiple timepoints post-dose (0 to 192 hours)

  3. Percentage of Alisertib Metabolites in Feces Following a Single Dose of [^14C]-Alisertib Oral Solution

    Total radioactive peak distributions of metabolites in 0 to 192 hours pooled fecal samples from participants.

    Time frame: Predose and multiple timepoints post-dose (0 to 192 hours)

  4. Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events

    An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) was defined as any AE at any dose that: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in a persistent or significant disability/incapacity or resulted in congenital anomaly/birth defect. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From first dose of study drug through 30 days after the last dose of study drug (Up to 117 days)

  5. Number of Participants With Clinically Significant Changes or Abnormalities in Clinical Laboratory Values Reported as AEs

    An abnormal laboratory was assessed to be an AE if the value lead to discontinuation or delay in treatment, dose modification, therapeutic intervention, or was considered by the investigator to be a clinically significant change from Baseline.

    Time frame: Part A: Day 1 and End of Study (EOS) Day 31 if not continuing to Part B, Part B: Days 8 and 15 of each cycle and EOS (Up to 117 days)

  6. Number of Participants With Clinically Significant Changes or Abnormalities in Vital Sign Measurements

    Vital signs included body temperature, heart rate, and sitting blood pressure. The investigator determined if the changes were clinically significant.

    Time frame: Part A: Day 1 and EOS (Day 31 if not continuing to Part B), Part B: Day 1 of each cycle and EOS (Up to 117 days)

07

Results

Posted Oct 31, 2018

Participant flow

Participants took part in the study at 1 investigative site in the United States from 24 January 2013 to 14 June 2013.

Part A
Participant flow — Part A
MilestoneAlisertib
Started3
Completed3
Not completed0
Part B
Participant flow — Part B
MilestoneAlisertib
Started3
Completed0
Not completed3
Withdrew: Progressive disease3

Outcome measures

PrimaryCmax: Maximum Observed Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · nanomole (nmol)/liter (L)
Cmax: Maximum Observed Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution
nanomole (nmol)/liter (L)Alisertib
Alisertib2183.3 ± 161.97
Drug-Related Material2606.7 ± 228.98
PrimaryTmax: Time of First Occurrence of Cmax for Alisertib and Drug-Related Material in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Median · hr
Tmax: Time of First Occurrence of Cmax for Alisertib and Drug-Related Material in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution
hrAlisertib
Alisertib1.00 ± 161.97
Drug-Related Material1.00 ± 228.98
PrimaryAUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · hour (hr)*nmol/L
AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution
hour (hr)*nmol/LAlisertib
Alisertib16800.0 ± 4936.60
Drug-Related Material37033.3 ± 20545.15
PrimaryAUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · hr*nmol/L
AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution
hr*nmol/LAlisertib
Alisertib17266.7 ± 5138.42
Drug-Related Material42233.3 ± 23302.43
PrimaryT1/2: Terminal Half Life for Alisertib and Drug-Related Material in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · hour
T1/2: Terminal Half Life for Alisertib and Drug-Related Material in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution
hourAlisertib
Alisertib23.40 ± 7.041
Drug-Related Material42.03 ± 25.255
PrimaryCL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Plasma Concentration for Alisertib Following a Single Dose of [^14C]-Alisertib Oral Solution
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Geometric mean · L/hr
CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Plasma Concentration for Alisertib Following a Single Dose of [^14C]-Alisertib Oral Solution
L/hrAlisertib
CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Plasma Concentration for Alisertib Following a Single Dose of [^14C]-Alisertib Oral Solution4.06 ± 25.6
PrimaryRatio of Whole Blood Total Radioactivity (TRA) Cmax to Plasma TRA Cmax
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · ratio
Ratio of Whole Blood Total Radioactivity (TRA) Cmax to Plasma TRA Cmax
ratioAlisertib
Ratio of Whole Blood Total Radioactivity (TRA) Cmax to Plasma TRA Cmax0.6550 ± 0.0671
PrimaryRatio of Alisertib Plasma Cmax to Drug-Related Material TRA Plasma Cmax
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · ratio
Ratio of Alisertib Plasma Cmax to Drug-Related Material TRA Plasma Cmax
ratioAlisertib
Ratio of Alisertib Plasma Cmax to Drug-Related Material TRA Plasma Cmax0.8397 ± 0.0589
PrimaryRatio of Whole Blood TRA AUClast to Plasma TRA AUClast
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · ratio
Ratio of Whole Blood TRA AUClast to Plasma TRA AUClast
ratioAlisertib
Ratio of Whole Blood TRA AUClast to Plasma TRA AUClast0.5950 ± 0.1010
PrimaryRatio of Alisertib Plasma AUClast to Drug-Related Material TRA Plasma AUClast
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · ratio
Ratio of Alisertib Plasma AUClast to Drug-Related Material TRA Plasma AUClast
ratioAlisertib
Ratio of Alisertib Plasma AUClast to Drug-Related Material TRA Plasma AUClast0.4997 ± 0.1364
PrimaryRatio of Whole Blood TRA AUC∞ to Plasma TRA AUC∞
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · ratio
Ratio of Whole Blood TRA AUC∞ to Plasma TRA AUC∞
ratioAlisertib
Ratio of Whole Blood TRA AUC∞ to Plasma TRA AUC∞0.6750 ± 0.0170
PrimaryRatio of Alisertib Plasma AUC∞ to Drug-Related Material TRA Plasma AUC∞
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · ratio
Ratio of Alisertib Plasma AUC∞ to Drug-Related Material TRA Plasma AUC∞
ratioAlisertib
Ratio of Alisertib Plasma AUC∞ to Drug-Related Material TRA Plasma AUC∞0.4490 ± 0.1204
PrimaryFe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Urine
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · percent of dose
Fe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Urine
percent of doseAlisertib
Fe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Urine2.650 ± 1.7935
PrimaryFe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Feces
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · percent of dose
Fe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Feces
percent of doseAlisertib
Fe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Feces87.833 ± 2.2898
PrimaryAe: Amount of [^14C]-Alisertib Excreted in Urine
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · nanogram equivalent [ng(eq)]
Ae: Amount of [^14C]-Alisertib Excreted in Urine
nanogram equivalent [ng(eq)]Alisertib
Ae: Amount of [^14C]-Alisertib Excreted in Urine939420.7 ± 632770.92
PrimaryAe: Amount of [^14C]-Alisertib Excreted in Feces
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · ng(eq)
Ae: Amount of [^14C]-Alisertib Excreted in Feces
ng(eq)Alisertib
Ae: Amount of [^14C]-Alisertib Excreted in Feces31156703.0 ± 764243.97
PrimaryPercent of Total Radioactivity (TRA) in Urine and Feces
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · percent of TRA
Percent of Total Radioactivity (TRA) in Urine and Feces
percent of TRAAlisertib
Percent of Total Radioactivity (TRA) in Urine and Feces90.500 ± 1.3115
PrimaryFe: Fraction of Administered Dose of Alisertib Excreted in Urine
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · percent of dose
Fe: Fraction of Administered Dose of Alisertib Excreted in Urine
percent of doseAlisertib
Fe: Fraction of Administered Dose of Alisertib Excreted in Urine0.009045 ± 0.000714
PrimaryAe: Amount of Alisertib Excretion in Urine
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · ng
Ae: Amount of Alisertib Excretion in Urine
ngAlisertib
Ae: Amount of Alisertib Excretion in Urine3215.0 ± 219.20
PrimaryRenal Clearance (CLR) of Alisertib
Time frame:
Predose and multiple timepoints post-dose (up to 240 hours)
Reported as:
Mean · L/hr
Renal Clearance (CLR) of Alisertib
L/hrAlisertib
Renal Clearance (CLR) of Alisertib0.000687 ± 0.000013
SecondaryPercentage of Alisertib Metabolites in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution

Total radioactive peak distributions of metabolites in 0 to 192 hours pooled plasma samples from participants.

Time frame:
Predose and multiple timepoints post-dose (0 to 192 hours)
Reported as:
Number · percent of plasma AUC0-192hr
Percentage of Alisertib Metabolites in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution
percent of plasma AUC0-192hrAlisertib
Metabolite M112.0
Metabolite M234.6
Metabolite M35.6
SecondaryPercentage of Alisertib Metabolites in Urine Following a Single Dose of [^14C]-Alisertib Oral Solution

Total radioactive peak distributions of metabolites in 0 to 192 hours pooled urine samples from participants.

Time frame:
Predose and multiple timepoints post-dose (0 to 192 hours)
Reported as:
Number · percent of dose
Percentage of Alisertib Metabolites in Urine Following a Single Dose of [^14C]-Alisertib Oral Solution
percent of doseAlisertib
Unknown0.24
M8a0.28
M90.66
M5360.14
M10.84
M80.37
Others0.05
SecondaryPercentage of Alisertib Metabolites in Feces Following a Single Dose of [^14C]-Alisertib Oral Solution

Total radioactive peak distributions of metabolites in 0 to 192 hours pooled fecal samples from participants.

Time frame:
Predose and multiple timepoints post-dose (0 to 192 hours)
Reported as:
Number · percent of dose
Percentage of Alisertib Metabolites in Feces Following a Single Dose of [^14C]-Alisertib Oral Solution
percent of doseAlisertib
M5364.45
M520a1.19
M3a2.22
M5502.96
M5379.17
M520b1.72
M320.82
M520c5.94
Alisertib26.27
M28.62
Others0
SecondaryNumber of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events

An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) was defined as any AE at any dose that: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in a persistent or significant disability/incapacity or resulted in congenital anomaly/birth defect. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From first dose of study drug through 30 days after the last dose of study drug (Up to 117 days)
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events
ParticipantsAlisertib
Any AE3
SAE0
SecondaryNumber of Participants With Clinically Significant Changes or Abnormalities in Clinical Laboratory Values Reported as AEs

An abnormal laboratory was assessed to be an AE if the value lead to discontinuation or delay in treatment, dose modification, therapeutic intervention, or was considered by the investigator to be a clinically significant change from Baseline.

Time frame:
Part A: Day 1 and End of Study (EOS) Day 31 if not continuing to Part B, Part B: Days 8 and 15 of each cycle and EOS (Up to 117 days)
Reported as:
Number · Participants
Number of Participants With Clinically Significant Changes or Abnormalities in Clinical Laboratory Values Reported as AEs
ParticipantsAlisertib
Neutrophil Count Decreased1
Neutropenia1
Blood Magnesium Decreased1
SecondaryNumber of Participants With Clinically Significant Changes or Abnormalities in Vital Sign Measurements

Vital signs included body temperature, heart rate, and sitting blood pressure. The investigator determined if the changes were clinically significant.

Time frame:
Part A: Day 1 and EOS (Day 31 if not continuing to Part B), Part B: Day 1 of each cycle and EOS (Up to 117 days)
Reported as:
Number · Participants
Number of Participants With Clinically Significant Changes or Abnormalities in Vital Sign Measurements
ParticipantsAlisertib
Number of Participants With Clinically Significant Changes or Abnormalities in Vital Sign Measurements0

Adverse events

Collected over From first dose of study drug through 30 days after the last dose of study drug (Up to 117 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alisertib—0/3 (0%)3/3 (100%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventAlisertib
FatigueGeneral disorders2/3
AlopeciaSkin and subcutaneous tissue disorders2/3
NauseaGastrointestinal disorders1/3
VomitingGastrointestinal disorders1/3
GlossodyniaGastrointestinal disorders1/3
PyrexiaGeneral disorders1/3
ChillsGeneral disorders1/3
Oedema peripheralGeneral disorders1/3
Back painMusculoskeletal and connective tissue disorders1/3
Musculoskeletal painMusculoskeletal and connective tissue disorders1/3

Baseline characteristics

Safety Population included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Alisertib
Mean64.0 ± 13.11
Sex: Female, Male
Sex: Female, Male(Participants)Alisertib
Female1
Male2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib
Not Hispanic or Latino3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib
White2
Black or African American1
Region of Enrollment
Region of Enrollment(participants)Alisertib
United States3
Height
Height(cm)Alisertib
Mean173.5 ± 7.15
Weight
Weight(kg)Alisertib
Mean80.27 ± 20.760
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Alisertib
Mean26.91 ± 8.346
08

Study locations

1 site
  • Comprehensive Clinical Development
    Tacoma, Washington 98418, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in Apr 2013, 2 months.

Results were first posted in Oct 2018, 5 years 6 months after primary completion.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 2 months is below that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2012
First posted
Oct 26, 2012
StartActual
Jan 24, 2013
Primary completionActual
Apr 4, 2013
CompletionActual
Jun 14, 2013
Results first posted
Oct 31, 2018
Last update
Oct 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01714947
Responsible party
Sponsor
First posted
Oct 26, 2012
Start date
Jan 24, 2013
Primary completion
Apr 4, 2013
Completion
Jun 14, 2013
Results posted
Oct 31, 2018
Last update
Oct 31, 2018

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion